公开(公告)号：EP3427738A1

公开(公告)日：2019-01-16

申请号：EP18177481.1

申请日：2010-06-17

申请人： Vertex Pharmaceuticals Incorporated

发明人： CHARIFSON, Paul ,  CLARK, Michael P. ,  BANDARAGE, Upul K. ,  BETHIEL, Randy S. ,  COURT, John J. ,  DENG, Hongbo ,  DRUTU, Ioana ,  DUFFY, John. P. ,  FARMER, Luc ,  GAO, Huai ,  GU, Wenxin ,  JACOBS, Dylan H. ,  KENNEDY, Joseph M. ,  LEDEBOER, Mark W. ,  LEDFORD, Brian ,  MALTAIS, Francois ,  PEROLA, Emanuele ,  WANG, Tiansheng ,  WANNAMAKER, Woods M. ,  BYRN, Randal ,  ZHOU, Yi ,  LIN, Chao ,  JIANG, Min ,  GERMANN, Ursula A. ,  JONES, Steven ,  SALITURO, Francesco G. ,  KWONG, Ann Dak-Yee

IPC分类号： A61K31/506 ,  A61P31/16

摘要： Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula ( I ):

or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula ( IA ) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula ( IA ) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

公开(公告)号：EP1689857A1

公开(公告)日：2006-08-16

申请号：EP04812485.3

申请日：2004-12-01

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： BYRN, Randal

IPC分类号： C12N5/08 ,  C12N7/00 ,  C12Q1/70 ,  A01N1/02

CPC分类号： A01N1/02 ,  A01N1/0221 ,  C12N5/067 ,  C12N2500/10 ,  C12N2500/14 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/18 ,  C12N2501/335 ,  C12N2501/70 ,  C12N2502/13

摘要： The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.

公开(公告)号：EP3068776A1

公开(公告)日：2016-09-21

申请号：EP14802787.3

申请日：2014-11-12

申请人： Vertex Pharmaceuticals Incorporated

发明人： NTI-ADDAE, Kwame, W. ,  WALDO, Michael ,  O'NEIL, Simon, Adam ,  VAN ALSTEN, John, Gregg ,  MACIKENAS, Dainius ,  MUDUNURI, Praveen ,  SHI, Yi ,  LEDEBOER, Mark, Willem ,  JURKAUSKAS, Valdas ,  MEDEK, Ales ,  JONES, Steven ,  BYRN, Randal ,  ASMAL, Mohammed ,  ROBERTSON, Sarah, Marie ,  TSAI, Wanjung

IPC分类号： C07D403/04 ,  C07D471/04 ,  A61K31/506 ,  A61P31/16

CPC分类号： C07D471/04 ,  A61K31/16 ,  A61K31/351 ,  A61K31/4965 ,  A61K31/506 ,  A61K45/06 ,  C07C309/30 ,  C07D403/04

摘要： Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

摘要翻译： 化合物（1）的多晶型或其药学上可接受的盐，其中化合物（1）由以下结构式表示：化合物（1）的HCl盐的形式A。化合物（1）的HCl盐的形式F ）.3H 2 O，化合物（1）的HCl盐的形式D，化合物（1）的形式A和化合物（1）的甲苯磺酸盐的形式A. 这样的多晶型用于治疗流感，抑制流感病毒的复制，或减少生物样品或受试者中流感病毒的数量。

公开(公告)号：EP3201221A1

公开(公告)日：2017-08-09

申请号：EP15779136.9

申请日：2015-10-01

申请人： Vertex Pharmaceuticals Incorporated

发明人： LEEMAN, Joshua Robert ,  BYRN, Randal ,  BENNETT, Hamilton Barlow ,  BARTELS, Douglas John

IPC分类号： C07K14/005

CPC分类号： C12Q1/701 ,  C07K14/005 ,  C07K16/1018 ,  C07K16/40 ,  C07K2317/34 ,  C12N7/00 ,  C12N9/1241 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12Q1/025 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Y207/07 ,  G01N33/5008 ,  G01N2333/11 ,  G01N2333/91245 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/52

摘要： The present invention relates to influenza A virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza A virus variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

摘要翻译： 本发明涉及甲型流感病毒变体，特别是对聚合酶抑制剂具有抗性的变体。 还提供了涉及甲型流感病毒变体的方法和组合物。 进一步提供了从患者分离，鉴定和表征多种病毒变体的方法。

公开(公告)号：EP2442809B1

公开(公告)日：2016-08-31

申请号：EP10726760.1

申请日：2010-06-17

申请人： Vertex Pharmaceuticals Incorporated

发明人： CHARIFSON, Paul ,  CLARK, Michael, P. ,  BANDARAGE, Upul, K. ,  BETHIEL, Randy, S. ,  COURT, John, J. ,  DENG, Hongbo ,  DRUTU, Ioana ,  DUFFY, John, P. ,  FARMER, Luc ,  GAO, Huai ,  GU, Wenxin ,  JACOBS, Dylan, H. ,  KENNEDY, Joseph, M. ,  LEDEBOER, Mark, W. ,  LEDFORD, Brian ,  MALTAIS, Francois ,  PEROLA, Emanuele ,  WANG, Tiansheng ,  WANNAMAKER, M., Woods ,  BYRN, Randal ,  ZHOU, Yi ,  LIN, Chao ,  JIANG, Min ,  GERMANN, Ursula, A. ,  JONES, Steven ,  SALITURO, Francesco G. ,  KWONG, Ann Dak-Yee

IPC分类号： A61K31/506 ,  A61P31/16

CPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D239/30 ,  C07D401/04 ,  C07D401/10 ,  C07D471/04

摘要： Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula ( I ): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula ( IA ) are as described herein. A compound is represented by Structural Formula ( IA ) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula ( IA ) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

摘要翻译： 抑制生物样品或患者中流感病毒复制，减少生物样品或患者中流感病毒数量和治疗患者流感的方法包括向所述生物样本或患者施用有效量的 由结构式（I）表示的化合物或其药学上可接受的盐，其中结构式（IA）的值如本文所述。 化合物由结构式（IA）或其药学上可接受的盐表示，其中结构式（IA）的值如本文所述。 药物组合物包含有效量的这种化合物或其药学上可接受的盐，以及药学上可接受的载体，佐剂或媒介物。

公开(公告)号：EP1381673B1

公开(公告)日：2009-05-13

申请号：EP02753872.7

申请日：2002-03-27

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： KWONG, Ann ,  BYRN, Randal ,  REID, Lola, M.

IPC分类号： C12N5/00 ,  C12N7/00 ,  C12N15/85 ,  C12N15/86 ,  C12Q1/70

CPC分类号： C12Q1/70 ,  C12N5/0031 ,  C12N5/0037 ,  C12N5/067 ,  C12N7/00 ,  C12N2500/20 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/12 ,  C12N2501/18 ,  C12N2501/335 ,  C12N2501/375 ,  C12N2501/39 ,  C12N2502/11 ,  C12N2770/24011

摘要： The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for injecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.

公开(公告)号：EP1381673A1

公开(公告)日：2004-01-21

申请号：EP02753872.7

申请日：2002-03-27

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： KWONG, Ann ,  BYRN, Randal ,  REID, Lola, M.

IPC分类号： C12N5/00 ,  C12N7/00 ,  C12N15/85 ,  C12N15/86 ,  C12Q1/70

CPC分类号： C12Q1/70 ,  C12N5/0031 ,  C12N5/0037 ,  C12N5/067 ,  C12N7/00 ,  C12N2500/20 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/12 ,  C12N2501/18 ,  C12N2501/335 ,  C12N2501/375 ,  C12N2501/39 ,  C12N2502/11 ,  C12N2770/24011

摘要： The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for injecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.

公开(公告)号：EP3578554A1

公开(公告)日：2019-12-11

申请号：EP19165859.0

申请日：2014-11-12

申请人： Vertex Pharmaceuticals Incorporated

发明人： NTI-ADDAE, Kwame W. ,  WALDO, Michael ,  O'NEIL, Simon Adam ,  VAN ALSTEN, John Gregg ,  MACIKENAS, Dainius ,  MUDUNURI, Praveen ,  SHI, Yi ,  LEDEBOER, Mark Willem ,  JURKAUSKAS, Valdas ,  MEDEK, Ales ,  JONES, Steven ,  BYRN, Randal ,  ASMAL, Mohammed ,  ROBERTSON, Sarah Marie ,  TSAI, Wanjung

IPC分类号： C07D403/04 ,  C07D471/04 ,  A61K31/506 ,  A61P31/16

摘要： Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula:

are Form A of HCl salt of Compound (1)· 1/2H 2 O, Form F of HCl salt of Compound (1)· 3H 2 O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

公开(公告)号：EP3068776B1

公开(公告)日：2019-05-29

申请号：EP14802787.3

申请日：2014-11-12

申请人： Vertex Pharmaceuticals Incorporated

发明人： NTI-ADDAE, Kwame, W. ,  WALDO, Michael ,  O'NEIL, Simon, Adam ,  VAN ALSTEN, John, Gregg ,  MACIKENAS, Dainius ,  MUDUNURI, Praveen ,  SHI, Yi ,  LEDEBOER, Mark, Willem ,  JURKAUSKAS, Valdas ,  MEDEK, Ales ,  JONES, Steven ,  BYRN, Randal ,  ASMAL, Mohammed ,  ROBERTSON, Sarah, Marie ,  TSAI, Wanjung

IPC分类号： C07D403/04 ,  C07D471/04 ,  A61K31/506 ,  A61P31/16

公开(公告)号：EP3141252B8

公开(公告)日：2019-03-13

申请号：EP16181549.3

申请日：2010-06-17

申请人： Vertex Pharmaceuticals Incorporated

发明人： CHARIFSON, Paul ,  CLARK, Michael, P. ,  BANDARAGE, Upul, K. ,  BETHIEL, Randy, S. ,  COURT, John, J. ,  DENG, Hongbo ,  DRUTU, Ioana ,  DUFFY, John, P. ,  FARMER, Luc ,  GAO, Huai ,  GU, Wenxin ,  JACOBS, Dylan, H. ,  KENNEDY, Joseph, M. ,  LEDEBOER, Mark, W. ,  LEDFORD, Brian ,  MALTAIS, Francois ,  PEROLA, Emanuele ,  WANG, Tiansheng ,  WANNAMAKER, M., Woods ,  BYRN, Randal ,  ZHOU, Yi ,  LIN, Chao ,  JIANG, Min ,  GERMANN, Ursula, A. ,  JONES, Steven ,  SALITURO, Francesco G. ,  KWONG, Ann Dak-Yee

IPC分类号： A61K31/506 ,  A61P31/16